Uncategorized

No podemos evitar que las bacterias se vuelvan resistentes a los antibióticos, pero sí demorar que eso suceda

Así lo afirma la bioquímica argentina María Soledad Ramírez, que dirige su propio laboratorio en la Universidad del Estado de California de Fullerton, Estados Unidos, en donde investiga los mecanismos de resistencia de la bacteria Acinetobacter baumannii (Ab), que integra …

No podemos evitar que las bacterias se vuelvan resistentes a los antibióticos, pero sí demorar que eso suceda Read More »

U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. FDA has granted accelerated approval of TALVEY™, a first-in-class bispecific antibody for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38

U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma Read More »

Scroll to Top